MIGNONE ROBERTO 4

What Happened
Roberto Mignone, a director of Teva Pharmaceutical Industries Ltd. (TEVA), was granted 7,242 restricted share units (RSUs) on May 28, 2026. The grant is reported at $0.00 per unit (an award/compensation grant) and is a derivative award that may settle in ordinary shares or cash.

Key Details

• Transaction date: May 28, 2026; filing date: June 1, 2026 (filed within the required two business days).
• Transaction type/code: Award/Grant (A) of 7,242 RSUs, grant price reported $0.00.
• Vesting: RSUs vest on May 28, 2027 (one-year vesting per filing).
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes: Each RSU represents a contingent right to one ordinary share or, at the committee's option, the cash value of one share (F1); grant made May 28, 2026 and vests May 28, 2027 (F2); ordinary shares may be represented by American Depositary Shares (ADS), each currently representing one ordinary share (F3).

Context
This is a compensation award (not a market purchase or sale) and generally reflects pay rather than a direct trading sentiment. The RSUs are derivative awards that will convert to shares or cash only if and when they vest and are settled.